Mon, Jul 14, 2014, 11:16 AM EDT - U.S. Markets close in 4 hrs 44 mins


% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • stocklasar stocklasar Apr 8, 2010 10:27 PM Flag

    Exciting Link: Exalgo & N-Type Ca Channel Research


    When I read the following paragraph, I was stunned.

    Has anyone yet understood the link between Exalgo and N-type Ca Channel research? I doubt any of you have.

    Because it's right in front of our faces "combinational effects of μ-opioids with Ca++ channel blockers").

    Many here have wondered why Neuromed was so hot to get its hands on CombinatoRx cHTS platform -- NOW YOU KNOW IF YOU KNOW WHAT I QUOTE BELOW MEANS--I hope you won't dismiss the following paragraph--

    "The mechanistic differences in μ-opioid analgesic effects also point to potential differences in susceptibility of Aδ and C fiber-mediated nociception to combinational effects of μ-opioids with Ca++ channel blockers. N-type Ca++ channels appear to be involved in conveying nociceptive messages into the central from the peripheral nervous system (13). Consistent with this, N-type Ca++ channels are highly concentrated in central terminals of primary afferents (14), and N-type Ca++ channel blockers have analgesic effects alone (15,16) and in combination with μ-opioids (17–19). Large doses of N-type Ca++ channel blockers given alone are generally necessary to produce significant analgesia, which may produce side effects (15), indicating a relatively small therapeutic index. In combination with opioids, however, Ca++ channel blockers appear to produce stronger analgesia (19). The nature of this interaction is not clear, however, in that some investigators have described additive effects (17) whereas others have reported pharmacologic synergy (18,19). These differences may be a result of undescribed differences in the types of afferent activity producing the pain or nociceptive responses under investigation. The purpose of this study was to investigate the effects of an N-type Ca++ channel blocker in a model of nociception in which the contribution of C and Aδ nociceptors has been defined (2,20) as well as to describe potential interactions between the μ-opioid morphine and an N-type Ca++ channel blocker."

    ****Neuromed needs cHTS (CombinatoRx) to do the kind of research described above.

    I submit Covidien buy-out is imminent if those Irish lads ever wake up... otherwise, watch out, Novartis or Sanofi-Aventis will snatch up this company.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is a 2001 article, but it is interesting, and I think the science is legitimate. There should be some more recent articles out there on the topic though.

      I think like Synavive, this is all about combining drugs to reduce or eliminate side effects and enhance efficacy. Sounds great!

      You had some weird attacks on this one Lasar. No one said Synavive could cure OA or RA. I had to laugh reading this one. It is clearly an ehanced low dose steroid to reduce inflammation. The steroid side effects are reduced as well. CombinatoRx has been very transparent about what it does, and what it does is worth billions.

      Keep it coming Lasar. Great stuff as far as I am concerned.

    • Do you know how many years Synavive in PH II? is the former president an idiot to give up a medicine that can cure OA and RA?
      sorry, bashing again...

    • hi,stocklosar,
      Could you please stop barking.
      This is an introduction of a junk paper and you take it as an important investing decision because you don't have any scientific background and know nothing about Ca++ channel. The introduction itself had controversial claim. The paper cited that 'N-type Ca++ channels are highly concentrated in central terminals of primary afferents'. it is absolutely nonsense to link the fact to Morphine which acts upon central nervous system.
      buddy, it is a stock not your lover...

1.1489+0.0089(+0.78%)11:11 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.